The Non-receptor-associated Tyrosine Kinase Syk is a Regulator of Metastatic Behavior in Human Melanoma Cells
Overview
Authors
Affiliations
Melanoma is one of the most aggressive neoplastic transformations and characterized by a high metastatic potential. The current study was performed to assess the impact of "spleen tyrosine kinase" (Syk), a non-receptor-associated tyrosine kinase, on growth and metastatic behavior of melanoma cells in vitro and in a severe combined immunodeficient (SCID)-mouse/human-melanoma xenotransplantation model in vivo. Syk was expressed in melanocytes but was found to be downregulated in melanoma cells. Vector-driven expression of Syk in two different melanoma cell lines did not influence growth speed, but significantly reduced the invasive growth potential of both cell lines in a Matrigel assay in vitro. In a SCID-mouse/human melanoma xenotransplantation model, Syk expressing Mel-Juso cells exhibited delayed and reduced tumor growth. After intravenous as well as subcutaneous injection of tumor cells, Syk-transfected cells formed significantly fewer metastatic tumor lesions than control cells. The presented data define Syk as a novel regulator of metastatic behavior of melanoma cells.
Denis V, Cassagnard N, Del Rio M, Cornillot E, Bec N, Larroque C PLoS One. 2022; 17(9):e0274390.
PMID: 36103569 PMC: 9473616. DOI: 10.1371/journal.pone.0274390.
Bona Fide Tumor Suppressor Genes Hypermethylated in Melanoma: A Narrative Review.
Guvenc C, Neckebroeck F, Antoranz A, Garmyn M, van den Oord J, Maria Bosisio F Int J Mol Sci. 2021; 22(19).
PMID: 34639015 PMC: 8508892. DOI: 10.3390/ijms221910674.
Buffard M, Naldi A, Freiss G, Deckert M, Radulescu O, Coopman P Biomolecules. 2021; 11(2).
PMID: 33670716 PMC: 7923165. DOI: 10.3390/biom11020308.
Kassouf T, Larive R, Morel A, Urbach S, Bettache N, Marcial Medina M Cancers (Basel). 2019; 11(12).
PMID: 31817924 PMC: 6966528. DOI: 10.3390/cancers11121974.
Proteomic identification of a marker signature for MAPKi resistance in melanoma.
Paulitschke V, Eichhoff O, Gerner C, Paulitschke P, Bileck A, Mohr T EMBO J. 2019; 38(15):e95874.
PMID: 31267558 PMC: 6669927. DOI: 10.15252/embj.201695874.